Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert O Cotes

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
The Journal of Clinical Psychiatry|May 31, 2023
Determining Clinical Follow-Up in the Context of Widening LAI Intervals: How Long Is Too Long?Samuel J Dotson, Robert O Cotes, Oliver Freudenreich
Case Reports in Psychiatry|July 12, 2017
A Case Report of Mania and Psychosis Five Months after Traumatic Brain Injury Successfully Treated Using OlanzapineGiordano F Cittolin-Santos, Jesse C Fredeen, Robert O Cotes
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|January 13, 2021
Revisiting an Anonymous Suggestion BoxAnn C Schwartz, Andrea Crowell, Marsha Stern, et al.
Journal of Psychiatric Practice|July 22, 2020
Integration of Clozapine-associated Harm Obsessions into Cognitive Behavioral Conceptualization and Treatment Planning for Thought Broadcasting: A Case StudySarah L Kopelovich, Keith Wood, Robert O Cotes, et al.
Psychiatry Research|December 31, 2025
Metabolic monitoring and control among patients with type 2 diabetes prescribed second generation antipsychoticsJiali Guo, David R Goldsmith, Robert O Cotes, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|June 22, 2019
Explorations with a Residency-Wide, Online, Anonymous Suggestion Box: A Roller Coaster RideMina Boazak, Robert O Cotes, Martha C Ward, et al.
Expert Review of Clinical Pharmacology|February 21, 2023
Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issuesJonathan G Leung, Megan Ehret, Raymond C Love, et al.
Focus (American Psychiatric Publishing)|January 25, 2020
Keeping Up With Changing Times in Education: Fostering Lifelong Learning of Millennial LearnersAnn C Schwartz, William M McDonald, Arshya B Vahabzadeh, et al.
Focus (American Psychiatric Publishing)|January 25, 2020
An Update on Promising Biomarkers in SchizophreniaDavid R Goldsmith, Courtney L Crooks, Elaine F Walker, et al.
JAMA Psychiatry|June 4, 2025
FDA Eliminates the Clozapine REMS-What Comes Next?Deanna L Kelly, John M Kane, Raymond C Love, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Psychiatry|May 31, 2023
Determining Clinical Follow-Up in the Context of Widening LAI Intervals: How Long Is Too Long?Samuel J Dotson, Robert O Cotes, Oliver Freudenreich
Case Reports in Psychiatry|July 12, 2017
A Case Report of Mania and Psychosis Five Months after Traumatic Brain Injury Successfully Treated Using OlanzapineGiordano F Cittolin-Santos, Jesse C Fredeen, Robert O Cotes
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|January 13, 2021
Revisiting an Anonymous Suggestion BoxAnn C Schwartz, Andrea Crowell, Marsha Stern, et al.
Journal of Psychiatric Practice|July 22, 2020
Integration of Clozapine-associated Harm Obsessions into Cognitive Behavioral Conceptualization and Treatment Planning for Thought Broadcasting: A Case StudySarah L Kopelovich, Keith Wood, Robert O Cotes, et al.
Psychiatry Research|December 31, 2025
Metabolic monitoring and control among patients with type 2 diabetes prescribed second generation antipsychoticsJiali Guo, David R Goldsmith, Robert O Cotes, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|June 22, 2019
Explorations with a Residency-Wide, Online, Anonymous Suggestion Box: A Roller Coaster RideMina Boazak, Robert O Cotes, Martha C Ward, et al.
Expert Review of Clinical Pharmacology|February 21, 2023
Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issuesJonathan G Leung, Megan Ehret, Raymond C Love, et al.
Focus (American Psychiatric Publishing)|January 25, 2020
Keeping Up With Changing Times in Education: Fostering Lifelong Learning of Millennial LearnersAnn C Schwartz, William M McDonald, Arshya B Vahabzadeh, et al.
Focus (American Psychiatric Publishing)|January 25, 2020
An Update on Promising Biomarkers in SchizophreniaDavid R Goldsmith, Courtney L Crooks, Elaine F Walker, et al.
JAMA Psychiatry|June 4, 2025
FDA Eliminates the Clozapine REMS-What Comes Next?Deanna L Kelly, John M Kane, Raymond C Love, et al.
Pageof 7